---
title: A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
nct_id: NCT02511340
overall_status: UNKNOWN
phase: PHASE2
sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Chronic Myelogenous Leukemia
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02511340.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02511340"
ct_last_update_post_date: 2015-07-30
last_seen_at: "2026-05-12T06:02:38.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

**Official Title:** Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients

**NCT ID:** [NCT02511340](https://clinicaltrials.gov/study/NCT02511340)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 167
- **Lead Sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Conditions:** Chronic Myelogenous Leukemia
- **Start Date:** 2013-01
- **Completion Date:** 2015-12
- **CT.gov Last Update:** 2015-07-30

## Brief Summary

Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.

## Detailed Description

Multi-center, single-arm, open-label,phase II study to investigate efficacy and safety of Flumatinib in Chinese patients with accelerated or blastic Phase chronic myelogenous leukemia. The starting daily oral dose of Flumatinib is 600mg，core test is six cycles (each cycle is 28 days), collecting the core test data for primary efficacy analysis. The longest treatment time is 12 cycles.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Male or female patients age 18-75 year-old;
* ECOG 0 - 2;
* Newly diagnosed or previously treated Ph+ CML patients in accelerated or blastic Phase;
* Adequate organ function;
* Written informed consent prior to any study procedures being performed.

Exclusion Criteria:

* Patients in Chronic and Blastic Phases;
* Previously treated with Flumatinib;
* Previously documented T315I mutations;
* Previous therapy within protocol defined timeframe, including:

  * hydroxyurea within 24 hr,
  * Imatinib or Nilotinib or Dasatinib within 28 days)
* Cardiac dysfunction ;
* History of congenital or acquired bleeding disorders unrelated to CML;
* Central nervous system leukemia;
* Previous malignancy except CML;
* Acute or chronic liver or severe kidney disease unrelated to CML;
* Pregnant, breastfeeding, child bearing potential but failed to take effective contraception.
```

## Arms

- **Flumatinib mesylate tablet 600 mg qd** (EXPERIMENTAL) — Flumatinib, 600mg, qd

## Interventions

- **Flumatinib mesylate tablet 600 mg qd** (DRUG) — Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients

## Primary Outcomes

- **Confirmed overall hematologic response（OHR）at 6 months** _(time frame: 6 months)_

## Locations (1)

- Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan, Hubei, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.union hospital tongji medical college huazhong university of science and technology|wuhan|hubei|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02511340.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02511340*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*